Cafelkibart’s entry into phase 3 is of note to Coherus.
ApexOnco Front Page
Recent articles
The company is starting four new pivotal trials this year.
The company discontinues its Yap/TEAD inhibitor IAG933 owing to lack of tolerability and efficacy.
Early data with the RIPTAC HLD-0915 look competitive.
The G12D-preferring QTX3034 has produced responses in endometrial and colorectal cancers.
An upcoming second-line SCLC phase 3 will include Imdelltra as a control option.
The company plans a pivotal pancreatic cancer trial after seeing two responses in eight patients.
AstraZeneca ended a tie-up with Asher, and then set off on its own.
